Yellow fever virus vaccination: an emblematic model to elucidate robust human immune responses
By preventing infectious diseases, vaccines contribute substantially to public health. Besides, they offer great opportunities to investigate human immune responses. This is particularly true for live-attenuated virus vaccines which cause resolving acute infections and induce robust immunity. The fa...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-08-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2021.1891752 |
| _version_ | 1827807680254705664 |
|---|---|
| author | Amandine Bovay Silvia A. Fuertes Marraco Daniel E. Speiser |
| author_facet | Amandine Bovay Silvia A. Fuertes Marraco Daniel E. Speiser |
| author_sort | Amandine Bovay |
| collection | DOAJ |
| description | By preventing infectious diseases, vaccines contribute substantially to public health. Besides, they offer great opportunities to investigate human immune responses. This is particularly true for live-attenuated virus vaccines which cause resolving acute infections and induce robust immunity. The fact that one can precisely schedule the time-point of vaccination enables complete characterization of the immune response over time, short-term and over many years. The live-attenuated Yellow Fever virus vaccine strain YF-17D was developed in the 1930’s and gave rise to the 17D-204 and 17DD vaccine sub-strains, administered to over 600 million individuals worldwide. YF vaccination causes a systemic viral infection, which induces neutralizing antibodies that last for a lifetime. It also induces a strong T cell response resembling the ones of acute infections, in contrast to most other vaccines. In spite of its use since 1937, learning how YF vaccination stimulates such strong and persistent immune responses has gained substantial knowledge only in the last decades. Here we summarize the current state of knowledge on the immune response to YF vaccination, and discuss its contribution as a human model to address complex questions on optimal immune responses. |
| first_indexed | 2024-03-11T22:00:50Z |
| format | Article |
| id | doaj.art-9f697a2ac6c0435a9f0fc88963351db4 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T22:00:50Z |
| publishDate | 2021-08-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-9f697a2ac6c0435a9f0fc88963351db42023-09-25T11:13:19ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2021-08-011782471248110.1080/21645515.2021.18917521891752Yellow fever virus vaccination: an emblematic model to elucidate robust human immune responsesAmandine Bovay0Silvia A. Fuertes Marraco1Daniel E. Speiser2University of BaselLausanne University Hospital and University of LausanneLausanne University Hospital and University of LausanneBy preventing infectious diseases, vaccines contribute substantially to public health. Besides, they offer great opportunities to investigate human immune responses. This is particularly true for live-attenuated virus vaccines which cause resolving acute infections and induce robust immunity. The fact that one can precisely schedule the time-point of vaccination enables complete characterization of the immune response over time, short-term and over many years. The live-attenuated Yellow Fever virus vaccine strain YF-17D was developed in the 1930’s and gave rise to the 17D-204 and 17DD vaccine sub-strains, administered to over 600 million individuals worldwide. YF vaccination causes a systemic viral infection, which induces neutralizing antibodies that last for a lifetime. It also induces a strong T cell response resembling the ones of acute infections, in contrast to most other vaccines. In spite of its use since 1937, learning how YF vaccination stimulates such strong and persistent immune responses has gained substantial knowledge only in the last decades. Here we summarize the current state of knowledge on the immune response to YF vaccination, and discuss its contribution as a human model to address complex questions on optimal immune responses.http://dx.doi.org/10.1080/21645515.2021.1891752yellow fever vaccinationimmune responset cellsb cells |
| spellingShingle | Amandine Bovay Silvia A. Fuertes Marraco Daniel E. Speiser Yellow fever virus vaccination: an emblematic model to elucidate robust human immune responses Human Vaccines & Immunotherapeutics yellow fever vaccination immune response t cells b cells |
| title | Yellow fever virus vaccination: an emblematic model to elucidate robust human immune responses |
| title_full | Yellow fever virus vaccination: an emblematic model to elucidate robust human immune responses |
| title_fullStr | Yellow fever virus vaccination: an emblematic model to elucidate robust human immune responses |
| title_full_unstemmed | Yellow fever virus vaccination: an emblematic model to elucidate robust human immune responses |
| title_short | Yellow fever virus vaccination: an emblematic model to elucidate robust human immune responses |
| title_sort | yellow fever virus vaccination an emblematic model to elucidate robust human immune responses |
| topic | yellow fever vaccination immune response t cells b cells |
| url | http://dx.doi.org/10.1080/21645515.2021.1891752 |
| work_keys_str_mv | AT amandinebovay yellowfevervirusvaccinationanemblematicmodeltoelucidaterobusthumanimmuneresponses AT silviaafuertesmarraco yellowfevervirusvaccinationanemblematicmodeltoelucidaterobusthumanimmuneresponses AT danielespeiser yellowfevervirusvaccinationanemblematicmodeltoelucidaterobusthumanimmuneresponses |